NCT06544265 - SynKIR-310 for Relapsed/Refractory B-NHL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

September 30, 2028

Study Completion Date

December 31, 2028

Conditions

B Cell LymphomaNHL, AdultMantle Cell LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaAggressive B-Cell Non-Hodgkin LymphomaIndolent B-Cell Non-Hodgkin LymphomaFollicular LymphomaMarginal Zone LymphomaDLBCL - Diffuse Large B Cell LymphomaHGBL With MYC and BCL2 and/or BCL6 RearrangementsHigh-grade B-cell LymphomaDiffuse Large B Cell LymphomaLarge B-cell LymphomaT-Cell/Histiocyte Rich LymphomaNon-hodgkin Lymphoma,B CellPrimary Mediastinal Large B-cell Lymphoma (PMBCL)Epstein-Barr Virus Positive DLBCL, NosFollicular Lymphoma Grade 3BDLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic InflammationHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedFollicular Lymphoma Grade 3Marginal Zone Splenic LymphomaDLBCL

Interventions

BIOLOGICAL

SynKIR-310

Autologous T Cells transduced with CD19 KIR-CAR

Trial Locations (5)

19104

ACTIVE_NOT_RECRUITING

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

30322

RECRUITING

Winship Cancer Institute of Emory University, Atlanta

66205

RECRUITING

The University of Kansas Cancer Center, Fairway

80218

RECRUITING

Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute, Denver

08902

RECRUITING

Rutgers Cancer Institute, New Brunswick